Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CERTs Risk Management Agenda Includes Tikosyn Study, Workshops

Executive Summary

The initial results from a CERT study of the risk management program for Pfizer's anti-arrhythmia drug Tikosyn (dofetilide) may indicate some practical limits to well-designed monitoring plans, Office of Postmarketing Drug Risk Assessment Director Peter Honig, MD, suggested Nov. 5
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS038811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel